These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2890459)

  • 1. Absorption studies of the H2-blocker nizatidine.
    Knadler MP; Bergstrom RF; Callaghan JT; Obermeyer BD; Rubin A
    Clin Pharmacol Ther; 1987 Nov; 42(5):514-20. PubMed ID: 2890459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bioavailability of nizatidine and ranitidine concurrently administered with antacid.
    Desager JP; Harvengt C
    J Int Med Res; 1989; 17(1):62-7. PubMed ID: 2565267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic profile of nizatidine in man.
    Callaghan JT; Bergstrom RF; Rubin A; Chernish S; Crabtree R; Knadler MP; Obermeyer B; Offen WW; Schneck DW; Aronoff G
    Scand J Gastroenterol Suppl; 1987; 136():9-17. PubMed ID: 2892261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interactions of H2-receptor antagonists.
    Bachmann KA; Sullivan TJ; Jauregui L; Reese J; Miller K; Levine L
    Scand J Gastroenterol Suppl; 1994; 206():14-9. PubMed ID: 7863246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nizatidine disposition in subjects with normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Bopp RJ; Sloan RS; Callaghan JT
    Clin Pharmacol Ther; 1988 Jun; 43(6):688-95. PubMed ID: 2897890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretion of nizatidine into human breast milk after single and multiple doses.
    Obermeyer BD; Bergstrom RF; Callaghan JT; Knadler MP; Golichowski A; Rubin A
    Clin Pharmacol Ther; 1990 Jun; 47(6):724-30. PubMed ID: 1972674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nizatidine, an H2-blocker. Its metabolism and disposition in man.
    Knadler MP; Bergstrom RF; Callaghan JT; Rubin A
    Drug Metab Dispos; 1986; 14(2):175-82. PubMed ID: 2870891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of oral nizatidine.
    Vargas R; Ryan J; McMahon FG; Regel G; Offen WW; Matsumoto C
    J Clin Pharmacol; 1988 Jan; 28(1):71-5. PubMed ID: 2895125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy.
    Lima M; Holdcroft C
    Nurse Pract; 1989 Feb; 14(2):41-2. PubMed ID: 2564655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly.
    Callaghan JT; Rubin A; Knadler MP; Bergstrom RF
    J Clin Pharmacol; 1987 Aug; 27(8):618-24. PubMed ID: 2888796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of interaction between nizatidine and warfarin during chronic administration.
    Cournot A; Berlin I; Sallord JC; Singlas E
    J Clin Pharmacol; 1988 Dec; 28(12):1120-2. PubMed ID: 2907521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nizatidine (AXID).
    Med Lett Drugs Ther; 1988 Aug; 30(772):77-8. PubMed ID: 2899835
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of the antacid Maalox and the H2-antagonist cimetidine on the pharmacokinetics of cerivastatin.
    Mück W; Ritter W; Dietrich H; Frey R; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):261-4. PubMed ID: 9208343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioequivalence of two oral formulations of nizatidine capsules in healthy male volunteers.
    Lockyer M; Al-Dgither S; Al-Gaai E; Yousuf A; Hammami MM
    Biopharm Drug Dispos; 2005 Apr; 26(3):117-20. PubMed ID: 15723428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of nizatidine in extemporaneous oral liquid preparations.
    Lantz MD; Wozniak TJ
    Am J Hosp Pharm; 1990 Dec; 47(12):2716-9. PubMed ID: 1980576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired bioavailability of famotidine given concurrently with a potent antacid.
    Barzaghi N; Gatti G; Crema F; Perucca E
    J Clin Pharmacol; 1989 Jul; 29(7):670-2. PubMed ID: 2569486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
    Stass H; Böttcher MF; Ochmann K
    Clin Pharmacokinet; 2001; 40 Suppl 1():39-48. PubMed ID: 11352441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
    Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
    Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of duodenal ulceration in the United States.
    Dyck WP; Cloud ML; Offen WW; Matsumoto C; Chernish SM
    Scand J Gastroenterol Suppl; 1987; 136():47-55. PubMed ID: 2892255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.
    Lin TM; Evans DC; Warrick MW; Pioch RP
    J Pharmacol Exp Ther; 1986 Nov; 239(2):406-10. PubMed ID: 2877081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.